Form 4: Artiva CEO Sells Shares to Cover Tax Obligations

Artiva Biotherapeutics CEO Fred Aslan sold 27,116 shares at an average price of $9.00 to satisfy tax withholding requirements.

Summary

• Fred Aslan, Chief Executive Officer and Director of Artiva Biotherapeutics, sold 27,116 shares of common stock on May 19, 2026.
• The shares were sold at a weighted average price of $9.0077, with individual transaction prices ranging from $8.7383 to $9.0104.
• The total value of the transaction was approximately $244,253.
• This sale was non-discretionary and conducted under a 'sell-to-cover' policy to meet tax withholding obligations related to the vesting of restricted stock units.
• Following this transaction, Fred Aslan continues to hold 1,535,082 shares of the company directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine event. While it involves an insider sale, the automatic nature for tax purposes means it does not reflect a change in the CEO's outlook on the company's value.

Positives

• The sale was non-discretionary and triggered automatically by company policy rather than a personal decision to divest.
• The CEO maintains a substantial ownership stake of over 1.5 million shares, aligning his interests with shareholders.
• The transaction was transparently reported and executed within a narrow price range.

Negatives

• The sale resulted in a reduction of the CEO's direct holdings by 27,116 shares.
• Market participants may occasionally view any insider selling as a lack of immediate upward momentum, regardless of the administrative reason.

Risks

• Future vestings of restricted stock units may trigger additional automatic sales, potentially creating minor downward pressure on the stock price.
• The stock price range during the sale ($8.7383 to $9.0104) indicates some intraday volatility.

Future Outlook

No specific forward-looking guidance was provided in this administrative filing; however, the CEO's continued high level of share ownership suggests long-term commitment to the company's strategic goals.

Management Comments

• The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are a standard administrative procedure in the biotechnology and broader tech sectors, used to manage the tax impact of equity-based compensation without signaling a change in executive sentiment.

Comparison to Industry Standards

• The use of a sell-to-cover policy is consistent with practices at other clinical-stage biotech companies like Fate Therapeutics or NKarta.
• The CEO's retention of over 98% of his position following a tax-related vesting event is in line with high-conviction management teams in the sector.

Corporate Governance

Related Party Transactions

• The reporting person, Fred Aslan, is the CEO and a Director, making this a related party transaction involving the sale of company equity.

Stakeholder Impact

• Shareholders: Minimal impact as the sale was for tax purposes and the CEO remains heavily invested.
• Regulatory: The filing demonstrates compliance with Section 16(a) of the Securities Exchange Act.

Next Steps

• Monitor future Form 4 filings for any discretionary (non-tax related) buying or selling by insiders.
• Observe upcoming clinical data readouts which typically drive the valuation of Artiva Biotherapeutics.

Key Dates

Recommendation

The filing represents a routine administrative transaction for tax purposes. It does not provide new fundamental data or change the investment thesis for the company. Investors should maintain their current positions pending more significant clinical or financial updates.

Keywords

Artiva Biotherapeutics, ARTV, Insider Trading, Fred Aslan, Sell-to-Cover, Restricted Stock Units, Biotechnology, Executive Compensation